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Abstract
I In nt tr ro od du uc ct ti io on n: :   The time course of pregnancy-associated plasma protein-A (PAPP-A)
levels was studied at admission, immediately after percutaneous coronary inter-
vention (PCI) and 1, 2, 4, 6, 12, 24 and 48 h after PCI in acute coronary syndrome
with ST segment elevation (ACS-STE) to determine the impact of PCI, concomi-
tant clinical complications and heparin administration. 
M Ma at te er ri ia al l   a an nd d   m me et th ho od ds s: :   Pregnancy-associated plasma protein-A serum levels,
examined by the KryptorTM system, were studied in 30 heparinized PCI ACS-STE
patients, in 10 elective PCIs and 12 coronary angiographies with heparin, and in
5 patients with normal coronary angiogram without heparin. 
R Re es su ul lt ts s: :   Heparin caused a high PAPP-A increase in ACS-STE patients, in all
patients with heparin without ACS and angiographic signs of significant ather-
osclerosis. This increase was directly associated with heparin dosage and acti-
vated clotting time (ACT) (r = 0.71, p = 0.0001) and inversely with the interval
between heparin applications and time of serum sampling. It was followed 
by a rapid decrease within 1 to 2 h and return to normal levels in 10 to 12 h. 
In ACS-STE patients the decrease was significantly slower than in heparinized
elective PCI and angiography patients. The PAPP-A increase was not significantly
dependent on the length of PCI. Persistent increase after 24 h was associated
in 4/7 patients with concomitant clinical complications.
C Co on nc cl lu us si io on ns s: :   The diagnostic validity of PAPP-A can be verified only within the 
1st h after clinical onset of ACS before heparin administration, the prognostic value
in heparinized patients not earlier than 12 h after the last heparin application, 
if ACT is normal and serious clinical concomitant complications are eliminated.
K Ke ey y   w wo or rd ds s: :   pregnancy-associated plasma protein-A, myocardial infarction, heparin,
percutaneous coronary intervention.
Introduction
Examination of increased pregnancy-associated plasma protein-A 
(PAPP-A) serum levels within the first 12 h of acute coronary syndrome
(ACS) development supports the hypothesis that it might be the earliest
marker of different types of ACS [1, 2], because of its presumed role in the
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development of atherosclerotic lesions [3], athero-
matous plaque instability [4] and its contribution
to adverse outcomes in ACS [5].
The study of PAPP-A kinetics in ACS patients indi-
cates that its pattern of release is variable. Preg-
nancy-associated plasma protein-A levels can be
influenced by the timing of reperfusion. Its eleva-
tion is followed by rapid normalization [6].
Comparison of the effect of primary percuta-
neous intervention (PCI) and thrombolytic thera-
py on increased PAPP-A levels revealed that the
effect of heparin administration on this increase
might not be eliminated [7]. The potential signif-
icance of concomitant heparin administration for
increased PAPP-A levels in ACS with ST elevation
(ACS-STE) was confirmed in animal experiments;
heparin  administration  was  associated  with
a rapid and significant increase in PAPP-A levels,
presumably due to the detachment of PAPP-A
from vessel walls [8]. This hypothesis was con-
firmed by a rapid increase of PAPP-A after intra-
venous  application  of  low  molecular  weight
heparin  (LMWH)  and  unfractionated  heparin
(UFH) in haemodialysis and angiography patients.
Repeated heparin boluses induced additional
PAPP-A release [9].
The aim of our work was to study the time
course of PAPP-A levels during the early phase of
ACS-STE after hospital admission to determine the
impact of other associated clinical factors, PCI, and
UFH/LMWH administration, including clinical com-
plications.
Material and methods
P Pa at ti ie en nt t   p po op pu ul la at ti io on n   a an nd d   s st tu ud dy y   d de es si ig gn n
The Internal Ethics Review Board of University
Hospital Motol approved this prospective study. All
study subjects signed informed consent prior to
coronary angiography. Clinical data were obtained
from  30  randomly  sampled  ACS-STE  patients
referred to our department (Table I) between Janu-
ary 18 and August 9, 2007 for primary PCI. 
Acute coronary syndrome with ST elevation was
characterized by prolonged chest pain with ST ele-
vation (> 1 mm in leads I, II, III, aVL and aVF or 
> 2 mm in two or more contiguous V1-6 leads). The
median time from the onset of symptoms to the
first sampling was 192 min (range 75-525 min).
Heparin was administered during transport to
the hospital in 29/30 patients (96.7%); 1 patient
arrived without heparin. In 22/30 patients additional
UFH concomitant with PCI was applied (ACS-STE +
aUFH). In 8/30 patients, no additional UFH, either
before or during primary PCI, was used, due to sat-
isfactory anticoagulation (ACS-STE + UFH). Efficacy
of anticoagulation therapy during PCI was moni-
tored using activated clotting time (ACT). Low
molecular weight heparin was administered after
sheath removal in 12/30 patients (40%).
The study is based on the exact timing of acute
chest pain onset, heparin (UFH/LMWH) adminis-
tration during transport, the first pre-PCI PAPP-A
examination, pre-PCI UFH administration, duration
of PCI, and consecutive examinations, starting
immediately after PCI and repeated at 1, 2, 4, 6, 12,
24, and 48 h after PCI. Pregnancy-associated plas-
ma  protein-A  was  examined  from  frozen  sera 
(–20°C), prepared within 1-2 h after blood sampling,
using the KryptorTM (Brahms, Germany) system,
which measured total PAPP-A, uncomplexed and
complexed, along with the proform of eosinophilic
major basic protein (proMBP). Intra- and inter-assay
variation coefficients were 7.5%.
For exact evaluation of UFH, PCI and angiogra-
phy influence on PAPP-A levels, three control groups
were selected: 1) 10 patients with elective PCI
receiving UFH (elective PCI+UFH), 2) 12 patients
without PCI, but UFH was administered because of
the radial approach or intracoronary ultrasonogra-
phy (ANG+UFH), 3) 5 patients without PCI, with
coronary angiography performed via the femoral
approach, without UFH administration and without
angiographic signs of atherosclerosis (ANG-UFH)
(Table I). Pregnancy-associated plasma protein-A
samples were drawn according to the same time
schedule as for ACS-STE, but only within 24 h. 
Curves for the PAPP-A time course were derived
from median levels and intervals between the start
of the PCI and the end of the procedure for all stud-
ied patients. For exact determination of normal
PAPP-A cut-off levels, PAPP-A levels of ANG-UFH
patients were compared with levels of patients
without coronary artery disease (CAD) from our pre-
vious study [2]. 
S St ta at ti is st ti ic ca al l   a an na al ly ys si is s
Nonparametric analyses were used due to the
non-Gaussian distribution of PAPP-A and other vari-
ables. Basic characteristics included median and
total range, eventually inter-quartile range. The
Mann-Whitney test was used for two group com-
parisons, the Kruskal-Wallis test for comparisons
among 3 or more groups. Post-hoc pair-wise com-
parisons (Table II) were done using the method of
unweighted groups [10]. The ˇ2 test or Fisher’s
exact test was used to compare the occurrence of
risk factors among the examined cohorts, Spear-
man’s  correlation  to  evaluate  the  relationship
between PAPP-A and ACT. Statistical analysis was
carried out using SPSS software (Release 17). 
Results
P Pa at ti ie en nt t   c ch ha ar ra ac ct te er ri is st ti ic cs s
The clinical characteristics are documented in
Table I. Patients treated with primary PCI were suc-Arch Med Sci 6, December / 2011 979
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A AC CS S- -S ST TE E   + +   U UF FH H A AC CS S- -S ST TE E   + +   a aU UF FH H E El le ec ct ti iv ve e   P PC CI I   + +   U UF FH H A AN NG G   + +   U UF FH H A AN NG G- -U UF FH H V Va al lu ue e   o of f   p p
( (N N = =   8 8) ) ( (N N = =   2 22 2) ) ( (N N = =   1 10 0) ) ( (N N = =   1 12 2) ) ( (N N = =   5 5) )
A Ag ge e   [ [y ye ea ar rs s] ] Mean ± SD 71.5 ±11.8 56.3.±12.3 64.7 ±2.4 64.7 ±8.3 53.7 ±6.2 *
Range 45.6-85.5 34.1-77.6 61.6-69.5 54.9-84.7 42.8-61.0
S Se ex x   n no o. .   ( (% %) ) Male 3 (37.5) 17 (77.3) 7 (70) 6 (50) 2 (40) NS
Female 5 (62.5) 5 (22.7) 3 (30) 6 (50) 3 (60) NS
R Ri is sk k   f fa ac ct to or rs s Hypertension 3 (37.5) 10 (45.5) 10 (100) 11 (92) 1 (20) *
n no o. .   ( (% %) )
Smoking 2 (25) 16 (72.7) 2 (20) 1 (8) 1 (20) *
Hyperlipo- 1 (12.5) 9 (40.9) 8 (80) 9 (75) 5 (100) *
proteinaemia
Diabetes mellitus 1 (12.5) 4 (18.2) 4 (40) 2 (17) 1 (20) NS
Diet 1 (12.5) 2 (9.1) 1 (10) 1 (8) 1 (20) NS
PAD 0 (0) 2 (9.1) 2 (20) 1 (8) 0 (0) NS
Insulin 0 (0) 0 (0) 1 (10) 0 (0) 0 (0) NS
BMI mean ± SD 26.9 ±2.9 29.8 ±4.9 28.3 ±3.6 26.5 ±3.8 27.0 ±3.8 NS
History of MI 0 (0) 1 (4.5) 1 (10) 0 (0) 0 (0) NS
History of stroke 3 (37.5) 1 (4.5) 0 (0) 1 (8) 0 (0) NS
History of 1 (12.5) 1 (4.5) 5 (50) 5 (42) 0 (0) *
revascularization
T Th he er ra ap py y Aspirin 2 (25) 2 (9.1)  8 (80) 5(42) 1 (20) *
n no o. .   ( (% %) )
ʲ-Blockers 3 (37.5) 2 (9.1) 6 (60) 7 (58) 2 (40) *
ACE inhibitors 1 (12.5) 6 (27.3) 9 (90) 8 (67) 0 (0) *
Nitrates 0 (0) 0 (0) 3 (30) 3 (25) 1 (20) *
Statins 0 (0) 1 (4.5) 7 (70) 7 (58) 3 (60) *
Calcium channel 0 (0) 1 (4.5) 1 (10) 1 (8) 0 (0) NS
blockers
Clopidogrel 0 (0) 9 (40.9) 4 (40) 3 (25) 0 (0) NS
E Ej je ec ct ti io on n   f fr ra ac ct ti io on n   ( (% %) ) 43.9 48.1 50.8 55.6 66.3 *
M Me ea an n   n nu um mb be er r   o of f   v ve es ss se el ls s    1.6 1.6 1.1 0.0 0.0 NS
w wi it th h   s st te en no os si is s   > >   5 50 0% %
C Cu ul lp pr ri it t RIA (%) 5 (62.5) 10 (45.5) 4 (40) 00
v ve es ss se el l
RCx (%) 0 3 (13.6) 2 (20) 00
ACD (%) 3 (27.5) 9 (40.9) 4 (40) 00
P PA AP PP P- -A A Mean ± SD 65.3 ±26.3 30.2 ±22.7 7.8 ±2.5 8.5 ±2.3 8.1 ±1.6
b be ef fo or re e
Median 59.3 19.0 7.6x 8.3x 8.2x
P PC CI I/ /a an ng gi io o
Range 34.3-123.1 6.8-85.2 4.0-12.4 4.9-14.2 5.6-10
H He ep pa ar ri in n Npt (%) 8 (100) 21 (95.4) 0 (0) 0 (0) 0 (0)
b be ef fo or re e
Mean ± SD 7125 ±2315 6405 ±2505 0 ±0 0 ±0 0 ±0
h ho os sp pi it ta al li iz za a-
Median 6000 5000 00 0 t ti io on n   [ [I IU U] ]
Range 5000-10000 5000-10000 0-0 0-0 0-0
H He ep pa ar ri in n Npt (%) 0 (0) 22 (100)  10 (100) 12 (100) 0 (0)
a at t s st ta ar rt t
Mean ± SD 0 ±0 7273 ±2562 9100 ±1114 6167 ±1760 0 ±0
o of f   P PC CI I   [ [I IU U] ]
Median 0 6000 10000 6000 0
Range 0-0 3000-10000 7500-10000 3000-10000 0-0
Npt – number of heparinized patients in particular groups, *p < 0.05, x – PAPP-A levels not influenced by previous heparin administration
T Ta ab bl le e   I I. . Characteristics of studied patients 
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cessfully reperfused in 29/30 (96.6%) of cases. The
median duration of intervention was 35 min (range
10-85 min). Stents were used in 29/30 cases (1.27
stents per patient, on average). No drug-eluting
stents were used. TIMI 0/1, at the beginning of the
procedure, was observed in 22 patients (73.3%) and
final TIMI 2/3 was observed in 28 patients (93.3%).
IIb/IIIa inhibitors were used in 5 patients (16.7%).
Two patients had ventricular fibrillation before
admission, one during the procedure, in one case
we observed the “no-reflow phenomenon” and in
two patients distal embolization or occlusion of
a side branch. One ACS-STE patient died (3.3%) on
the 45th day from pulmonary embolization. 
P PA AP PP P- -A A   l le ev ve el ls s   i in n   p pa at ti ie en nt ts s   w wi it th ho ou ut t   A AC CS S, ,   
b be ef fo or re e   U UF FH H   a ad dm mi in ni is st tr ra at ti io on n
Median control levels in patients without CAD
(ANG-UFH; 40 measurements) from the present
study and from the years 2001-2007 (96 patients)
corresponded to 6.8 (interquartile range (IR) was
5.6-7.9) and 6.5 mIU/l respectively [2], without any
statistically significant difference (p = 0.39). The
95th percentile levels from both studies were in the
range of 9.3-9.7 mIU/l. Therefore, the PAPP-A cut-
off levels are over 10.0 mIU/l.
The median PAPP-A levels before UFH adminis-
tration in patients with elective PCI (elective PCI +
UFH; 7.6 mIU/l; IR 5.8-9.6) or coronary angiography
(ANG + UFH; 8.3 mIU/l; IR 6.9-9.6) were all under
the 95th percentile cut-off level (Table I).
I Im mp pa ac ct t   o of f   U UF FH H/ /L LM MW WH H   o on n   P PA AP PP P- -A A   l le ev ve el ls s   
i in n   A AC CS S- -S ST TE E   p pa at ti ie en nt ts s   b be ef fo or re e   a an nd d   a af ft te er r   P PC CI I
Increased PAPP-A levels in heparinized ACS-STE
patients before primary PCI were found in 28/29
patients (Table I). The median interval from UFH
administration to admission/PAPP-A sampling was
90 min; range 15-220 min. In one of the heparinized
patients, with a BMI of 27 kg/m2 and 5000 IU of
UFH before admission, the level of PAPP-A remained
normal. In one patient without UFH, PAPP-A was 
> 10 mIU/l within 120 min after acute chest pain.
An inverse relationship of the interval length
from UFH administration and increased PAPP-A
admission levels was revealed (Figure 1). These
data indicate that pre-admission clearance of
PAPP-A levels was highest within the 1st h after
UFH administration, corresponding to 40 mIU/l
per  hour.  During  the  second  hour,  it  fell  to 
10 mIU/l per hour. 
The admission, pre-PCI PAPP-A levels in the sub-
group of ACS-STE patients requiring additional UFH
(ACS-STE + aUFH), because of insufficient ACT lev-
els, were lower than in patients with satisfactory
anticoagulation for PCI – ACS-STE+UFH (medians
19.0  (IR  14.7-30.0)  vs.  59.3  (34.9-66.5)  mIU/l; 
p = 0.002; Figure 2 A and Table I). This observation
was confirmed by a significant relationship between
ACT and PAPP-A levels (r = 0.78; p = 0.0001). 
The rapid and substantial increase of PAPP-A lev-
els after concomitant PCI additional heparin in ACS-
STE + aUFH patients was followed by a rapid
decrease within the first 4 h (Figure 2 A), followed
by a slow return to levels < 10 mIU/l within 12 h.
The duration of PCI, indicating the potential clini-
cal severity of the procedure, did not influence
PAPP-A levels. Pregnancy-associated plasma pro-
tein-A levels after PCI lasting ≤ 30 min compared
to 31-60 min PCI were 91.7 (IR was 64.6-144.9) vs.
77.9 (IR 45.8-163.4) mIU/l; p = 0.63. 
The direct impact of UFH administration on
increasing  PAPP-A  levels  was  related  to  its
dosage, with a rapid increase within the 1st h 
(Figure 2 B) and return to normal levels within 12 h.
Patients with a lower level of ACT corresponding
to  lower  admission  level  of  PAPP-A  received
a higher dose of heparin (10 000 IU) concomi-
tantly with PCI that induced the highest level of
PAPP-A after the end of PCI (Figure 2 B). A signif-
icant increase of PAPP-A levels was also observed
n n/ /N N T TR R   [ [h h] ] S St ta at ti is st ti ic ca al l   c co om mp pa ar ri is so on ns s
A AC CS S- -S ST TE E 24/30 12 (14-48) xx
+ +   U UF FH H   a an nd d
A AC CS S- -S ST TE E   
+ +   a aU UF FH H
E El le ec ct ti iv ve e   P PC CI I    9*/10 4.3 (2-12) xx
+ +   U UF FH H
A AN NG G   + +   U UF FH H 10*/12 5.4 (4-6.3) xx
V Va al lu ue e   o of f   p p < 0.05 < 0.05 NS
n – number of patients with return of PAPP-A levels < 10 mIU/l, 
N – number of studied patients, *number of patients with all exami-
nations within 24 h, x – comparison of studied patients, TR – time nec-
essary for the PAPP-A return to < 10 mIU/l 
T Ta ab bl le e    I II I. . Comparison  of  PAPP-A  normalization
between groups with ACS-STE, elective PCI and
angiography patients without PCI
70
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after LMWH administration (11.7 (IR 10.1-17.1) vs.
9.1 (7.6-11.1) mIU/l; p = 0.005), applied within 24 h
after PCI, to prevent imminent thrombotic com-
plications. 
I Im mp pa ac ct t   o of f   U UF FH H   o on n   P PA AP PP P- -A A   l le ev ve el ls s   i in n   p pa at ti ie en nt ts s
w wi it th ho ou ut t   A AC CS S   
The identical rapid, large increase of PAPP-A lev-
els, after UFH administration before elective PCI 
or coronary angiography, provides evidence that
UFH is mainly responsible for the rapid release of
PAPP-A and is not related to the CAD, PCI or angiog-
raphy. The PAPP-A peak level appeared 20 min after
the start of the procedures; levels in diagnostic
angiography without UFH remained unchanged,
under the cut-off level.
The  dynamics  of  the  initial  PAPP-A  level
changes in patients with elective PCI and angiog-
raphy  with  UFH  were  similar  to  those  in
heparinized ACS-STE patients. Our pilot study data
indicate that the normalization of PAPP-A levels
is quicker, i.e. within 4 to 5 h, than in ACS-STE
patients (Table II). The median time needed for
normalization  of  PAPP-A  levels  in  ACS-STE
patients  was  12.0  h,  whereas  in  heparinized
patients with elective PCI and angiography it was
4.33 h and 5.45 h, respectively (p < 0.05; Table II).
The  ACS-STE  patients  with  additional  LMWH
administration after PCI were eliminated from this
comparison (Figure 3).
A AC CS S- -S ST TE E   p pa at ti ie en nt ts s   w wi it th ho ou ut t   l la ab bo or ra at to or ry y   
n no or rm ma al li iz za at ti io on n   o of f   P PA AP PP P- -A A   w wi it th hi in n   2 24 4   h h   a af ft te er r   P PC CI I
In 7/30 STEMI patients, PAPP-A levels > 10 mIU/l
persisted even after 24 h. In 2/7 patients, a large
groin haematoma was observed. In 1 patient severe
three-vessel disease was found and in one PCI
failed to open the infarcted artery. In 3/7 pa  tients,
hospitalization ran a normal course.
Discussion
Exact timing of PAPP-A examination allowed the
ascertainment of its diagnostic validity by evalua-
tion of the influence of PCI-angiography procedures,
early clinical complications and heparin application. 
To our best knowledge, this is the first system-
atic PAPP-A ACS-STE study without any patient
selection bias that confirms previous suggestive
evidence  concerning  UFH/LMWH  influence  on
increased  PAPP-A  levels  in  serum  of  ACS-STE
patients [6, 8, 9].
Detected levels of PAPP-A can be influenced by
assay sensitivity and antibody specificity [11]. The
examination of frozen sera using the KryptorTM
system assured rapid and reliable examination of
total PAPP-A levels, with the same cut-off level of
< 10 mIU/l as in other studies [3, 8]. 
Admission PAPP-A levels were increased in all
ACS-STE patients who had been heparinized before
admission, except for a patient (BMI 27 kg/m2) 
with an insufficient dose of heparin. The increased 
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PAPP-A level in a patient without heparin, 2 h after
the  onset  of  acute  chest  pain,  suggests  that
increased PAPP-A might be a valuable biomarker
within the 1st h of ACS before the first UFH/LMWH
administration. 
Heparin administration was associated with
a rapid and substantial PAPP-A increase, not only
in ACS-STE patients (Figures 2 A-B), but also in all
patients without ACS and even in patients without
angiographic signs of significant atherosclerosis
(Figure 3). Angiography, without UFH, did not cause
PAPP-A increase (Figure 3). Therefore, increases in
PAPP-A are directly linked to UFH or LMWH admin-
istration [8, 9].
The effect of heparin on PAPP-A levels increase
was  directly  related  to  the  therapeutic  dose 
(Figure 2 B), significantly correlated with ACT lev-
els  and  inversely  correlated  with  the  interval
between application and time of serum sampling
(Figure 1). This corresponds to our observation that
in ACS-STE patients, without necessary PCI con-
comitant heparin administration because of high
ACT, the PAPP-A levels were significantly increased
without the typical peak directly after PCI UFH appli-
cation (Figure 2 A), followed by a continual PAPP-A
decrease.
The PAPP-A level increase appeared not to be
significantly dependent on the performance of PCI
and its length, or on diagnostic arteriography (Fig-
ure 3), suggesting that the rapid PAPP-A increase
after PCI is mainly due to the additional heparin
administration [8].
The rapid increase of PAPP-A after PCI concomi-
tant UFH therapy was followed by a rapid decrease
within 1-2 h, with return to normal levels < 10 mIU/l
in 80% of ACS-STE patients (24/30) within 10-12 h, in
agreement with previous data [8], compared to
amore rapid normalization in heparinized elective PCI
and angiography patients (Table II, Figures 2 A-B and
Figure 3). The slower return to normal PAPP-A levels
in ACS-STE patients and persistence of increased
PAPP-A in some of them might also be related to 
atherosclerotic lesions/plaque instability. Moreover,
PAPP-A levels > 10 mIU/l persisting in ACS-STE
patients after 24 h might also be associated with seri-
ous  clinical  complications,  such  as  large  groin
haematomas, unsuccessful opening of an infarct
artery or severe three-vessel disease. The impact of
different early complications in ACS-STE patients on
PAPP-A levels should be verified by further studies.
Our results indicate that the individual prognos-
tic validity of PAPP-A levels in ACS can be verified
not earlier than 12 h after UFH application (Table II),
if the ACT control levels are in the normal range and
if other clinical complications, including tumours,
are excluded [12]. It is necessary to consider also
individual variation in pharmacogenetic inactiva-
tion of UFH/LMWH.
Increased release of PAPP-A from unstable plaque
or an affected coronary artery wall after plaque
abruption is supported by slower clearance of
PAPP-A in ACS-STE patients and the (otherwise
unexplained) persistence of > 10 mIU/l levels after
24/48 h in some of our patients. Our findings are in
agreement  with  previous  observations  that
increased PAPP-A levels in pre-transplant plasma are
predictive of post-transplant cardiovascular events
[13], including an increased risk of death in AMI
patients with initially elevated PAPP-A levels [14]. 
The mechanism of rapid PAPP-A increase in
heparinized ACS-STE, elective PCI, and angiography
patients without CAD might be explained by the
affinity of heparin to PAPP-A [15]. Moreover, heparin
effectively competes for PAPP-A cell surface bind-
ing sites [16], which might explain the rapid PAPP-A
increase, since PAPP-A is expressed ubiquitously in
human coronary artery endothelium and vascular
smooth muscle [17]. This explanation is supported
by  our  finding  of  a UFH  dose-related  PAPP-A
increase in patients without ACS, as well as in
heparinized dialysis and angiography patients [9].
Increased PAPP-A levels might also be due to its
strong expression in atherothrombotic plaques 
in vivo [18] in ACS-STE patients. This is in agreement
with the observed slower clearance of UFH in our
patients and the persistence of increased levels, in
some patients, after 48 h. Increased levels of the
free PAPP-A fraction, in ACS without ST segment
elevation and UFH administration before admission,
provide additive prognostic information of 1-year
outcome in forecasting death and non-fatal myocar-
dial infarction [19, 20].
UFH-induced rapid release of PAPP-A from coro-
nary vessel walls may also contribute to the stabi-
lization of ruptured plaques, since PAPP-A prote-
olytic activity is bound, by adhesion, to cell surfaces
and makes IGF-1 available through cleavage of IGF-
BP-4 [8]. The beneficial role of UFH due to the mas-
sive release of PAPP-A, not only from coronary arter-
ies, might enhance the influx of growth factors,
which target damaged myocardial cells in response
to the accompanying increase of IGF-1 [21] corre-
sponding to PAPP-A accumulation in healing tis-
sues [22].
Clearance of PAPP-A includes not only elimina-
tion by the kidneys, but also its re-association with
cell surfaces, presumably in damaged regions. This
possibility is suggested by our observation that the
rapid, UFH dose-related increase of PAPP-A does not
influence the time of its rapid decrease (Figure 2 B).
Heparin is recognized as an anticoagulation
strategy in ACS-STE patients treated with PCI [23].
Nevertheless, our results provide evidence that in
heparin treated ACS-STE patients, PAPP-A does not
have diagnostic validity as an early biomarker. Diag-
nostic validity of PAPP-A in ACS requires PAPP-AArch Med Sci 6, December / 2011 983
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ascertainment before the first UFH/LMWH appli-
cation within the first few hours after clinical onset.
Prognostic implementation has to take into account
the time of UFH/LMWH administration, its clear-
ance and concomitant serious clinical complications.
Our results have to be confirmed by further stud-
ies in all types of ACS. Our PAPP-A examination is
based on the ascertainment of total PAPP-A levels
without evaluation of roles of uncomplexed PAPP-
A and proMBP, which is associated with PAPP-A and
regulates its physiological activity [4].
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